@article{51977db6ced64eed907816e35cd1992d,
title = "Nanomaterials for Therapeutic RNA Delivery",
abstract = "Recent years have witnessed tremendous developments and breakthroughs in the field of RNA-based therapeutics. The distinct mechanisms of exogenous RNAs and analogs, including messenger RNAs, small interfering RNAs, microRNAs, and antisense oligonucleotides, have brought them unprecedented potential to treat a variety of pathological conditions. However, the widespread application of RNA therapeutics is hampered by their intrinsic features (e.g., instability, large size, and dense negative charge) and formidable host barriers. Development of safe and efficient vectors is key for successful delivery and translation of RNA therapeutics. In this review, we first present an overview of RNA therapeutics and their clinical translation. We then discuss their delivery challenges and highlight recent advances in nanomaterial-based RNA-delivery platforms. Finally, the potential concerns and future developments of RNA delivery systems are discussed.",
keywords = "RNA delivery, drug delivery, gene therapy, nanomaterials, nanomedicine, vaccine",
author = "Xuexiang Han and Mitchell, {Michael J.} and Guangjun Nie",
note = "Funding Information: G.N. acknowledges the National Basic Research Plan of China ( 2018YFA0208900 ), the Strategic Priority Research Program of Chinese Academy of Sciences ( XDB36000000 ), the Key Research Program of Frontier Sciences CAS ( ZDBS-LY-SLH039 ), and the K.C. Wong Education Foundation ( GJTD-2018-03 ). M.J.M. acknowledges support from a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI), a US National Institutes of Health Director's New Innovator Award ( DP2 TR002776 ), a grant from the American Cancer Society ( 129784-IRG-16-188-38-IRG ), the National Institutes of Health ( R01 CA241661 , R37 CA244911 , R01 DK123049 , and UL1 TR001878 ), an Abramson Cancer Center -School of Engineering and Applied Sciences Discovery Grant ( P30 CA016520 ), a grant from the Institute for Translational Medicine and Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics, and a 2018 AACR-Bayer Innovation and Discovery Grant , number 18-80-44-MITC . The authors also thank Dr. Rachel S. Riley for helpful feedback and discussion. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = dec,
day = "2",
doi = "10.1016/j.matt.2020.09.020",
language = "English (US)",
volume = "3",
pages = "1948--1975",
journal = "Matter",
issn = "2590-2393",
publisher = "Cell Press",
number = "6",
}